Replies to post #2300 on Momenta Pharmaceuticals, Inc. (MNTA)

[acgood]

If I were running this business the Incentive for getting Marketing Approval for Copaxone would have been structured like this

Marketing approval before March 2012 - 300K shares
Marketing approval before March 2013 - 200K shares
Marketing approval before March 2015 - 100K shares

Currently, the only incentive to get this approval done as quickly as possible before 2015 is the immediate vesting of half of the shares on approval date

That structure would only make sense if the timing and likelihood of FDA M356 approval had any correlation to effort or actions of the MNTA named executive officers. I would argue that at this point, it largely does not.